Review of Research on Public Venture Capital and Its Future Prospects

2021 ◽  
Author(s):  
Yuxin Ning ◽  
Tingting Chu
2019 ◽  
Vol 20 (4) ◽  
pp. 978-1006 ◽  
Author(s):  
LEON GOOBERMAN ◽  
TREVOR BOYNS

Between 1976 and 1994 the UK Government’s Welsh Development Agency made 2,304 loan and equity investments totaling £117.8 million. The agency aimed to address difficulties faced by firms in obtaining finance, and such intervention was justified by the market failure and spillover hypotheses. This article assesses the agency’s investment activities against both justifications. It finds that while some investments succeeded, the portfolio’s financial performance was poor, and the agency did not address widespread market failure. Evidence of spillover returns existed, but cannot be quantified accurately across the portfolio. The article argues that the agency’s two venture capital objectives, to assemble a profitable portfolio and to grow employment levels through boosting commercial activity, were incompatible within a poorly performing regional economy. Although spillovers can justify public venture capital in such economies, expectations as to financial performance should be realistic in the absence of an ecosystem that facilitates demand for capital.


2015 ◽  
Vol 60 ◽  
pp. 63-72 ◽  
Author(s):  
Eric Afful-Dadzie ◽  
Zuzana Komínková Oplatková ◽  
Stephen Nabareseh

2010 ◽  
Vol 19 (7-8) ◽  
pp. 303-323 ◽  
Author(s):  
Cécile Carpentier ◽  
Jean-Marc Suret

Author(s):  
Michael Kinch

The withdrawal of large company support for early stage research, combined with shrinking Federal expenditures, has created a “Valley of Death” in drug discovery that creates both pressing challenges and extraordinary opportunities. This chapter details the opportunities that could be created by incentivizing new innovative and entrepreneurial research into novel medicines. Many “experiments” are currently under way to identify novel means of addressing the Valley of Death and successful examples include a partnership between Yale University and Gilead Sciences, a California biotechnology company. We also explore the potential and limitations of academia rising as a means to address the need for early-stage drug research and conclude the chapter and the book with the idea that the Federal government could play a key role were it to more actively and creatively function as both the largest source of public venture capital as well as the key regulator of new medicines.


2022 ◽  
pp. 194-221
Author(s):  
Luke Pittaway ◽  
Paul Benedict ◽  
Zsolt Bedő ◽  
Katalin Erdős ◽  
Eli Flournoy

This chapter considers the role of venture funding in the entrepreneurial university. It begins by discussing the literature on the entrepreneurial university, focusing on the role of financing. The literature shows that there are gaps in the financing of academic and graduate ventures. The second part of the chapter introduces short case examples that illustrate different forms of university-led venture funding, demonstrating how different universities have sought to fill funding gaps by means of seed capital grants, micro-financing, small business research grants, crowdfunding, social impact investing, seed capital investing, public venture capital, and venture capital. The chapter concludes by arguing that universities have sufficient resource endowments and human capital to address many funding gaps through innovative thinking and practice.


Sign in / Sign up

Export Citation Format

Share Document